ArticleAmerican journal of cancer research2026
Neoadjuvant chemotherapy followed by limb-sparing surgery for osteosarcoma: a retrospective cohort study on efficacy, safety, and prognostic factors.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study evaluated the outcomes of neoadjuvant chemotherapy (NACT) combined with limb-sparing surgery (LSS) for osteosarcoma (OS). A total of 204 OS patients treated at West China Hospital, Sichuan University between February 2020 and February 2023 were enrolled. Based on treatment modalities, patients were assigned to a control group (n=100; undergoing LSS) and an observation group (n=104; receiving NACT+LSS). Comparative analyses were performed to assess clinical outcomes, safety, inflammatory markers (C-reactive protein [CRP], tumor necrosis factor [TNF]-α), tumor-associated biomarkers (carcinoembryonic antigen [CEA], serum alkaline phosphatase [ALP], lactate dehydrogenase [LDH]), humoral immunity indicators (immunoglobulin [Ig] A/M/G), and 3-year prognosis (including metastasis and survival). Univariate and multivariate binary logistic regression analyses were conducted to identify independent determinants of therapeutic responses. Compared with the control group, the observation group demonstrated notably superior overall response and 3-year survival rates, while the overall incidence of adverse events was comparable, with no significant increase in severe adverse reactions. After intervention, both groups exhibited significant reductions in CRP, TNF-α, CEA, ALP, LDH, and IgA/M/G levels, with the observation group showing lower CRP, TNF-α, CEA, ALP, and LDH and higher IgA/M/G than the control group. Additionally, the 3-year incidence of lung metastasis was significantly lower in the observation group. Multivariate regression analysis identified maximum tumor diameter ≥7.8 cm, LSS alone, and elevated CEA as independent risk factors for poor treatment response, while increased IgA levels emerged as an independent protective factor. These results support the clinical benefit of NACT combined with LSS in OS, without increasing the risk of adverse events or severe specific adverse reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.